infants at highest risk of RSV

Resources

Help guide your patients and their parents or caregivers with these tools and resources.

Infants at higest risk RSV

Identifying High-risk Patients

  • Patient ID Kit

    Resources to help identify, record, and support your patients who could benefit from SYNAGIS

  • Patient Eligibility Grid

    Helps identify high-risk patients who are eligible for SYNAGIS

  • Editable Patient ID Log

    Allows you to identify and track eligible patients during the RSV season

  • 2014 AAP Birthday Guide

    Interactive guide that simplifies identifying infants who are at the highest risk for severe RSV disease during the 2023-2024 RSV season according to the 2014 AAP guidance

  • 2018 NPA Birthday Guide

    Interactive guide that simplifies identifying infants who are at the highest risk for severe RSV disease during the 2023-2024 RSV season according to the 2018 NPA guidelines

Other Resources

Tools to help you in your practice

  • NICU FIrst Dose

    Demonstrates the importance of receiving the first dose of SYNAGIS in the NICU, before a patient is discharged to the outpatient setting

  • Coordinator Resource Catalog

    Features a catalog of SYNAGIS resources that are available to parents and caregivers

RSV Education for Your Patients

RSV Factsheet

Contains information about what RSV is and premature infants at high risk

View form en español

SYNAGIS Information for Your Patients

SYNAGIS brochure

Educate Parents/Caregivers about SYNAGIS and why their baby may be at high risk

View form en español

AAP=American Academy of Pediatrics; NICU=neonatal intensive care unit; NPA=National Perinatal Association; RSV=respiratory syncytial virus. 

All imagery is for illustrative purposes only.
 

ALL INFANTS ARE NOT THE SAME

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

  • with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
  • with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
  • with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions: Anaphylaxis and anaphylactic shock (including fatal cases) and other severe acute hypersensitivity reactions have been reported. Permanently discontinue SYNAGIS and administer appropriate medication if such reactions occur.

Coagulation Disorders: SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder.

RSV Diagnostic Test Interference: Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Serious Adverse Reactions: The most common serious adverse reactions occurring with SYNAGIS are anaphylaxis and other acute hypersensitivity reactions.

Most Common Adverse Reactions: The most common adverse reactions are fever and rash.

Postmarketing Experience: Severe thrombocytopenia and injection site reactions have been identified during post approval use of SYNAGIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

LIMITATIONS OF USE

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

CONTRAINDICATIONS

Previous significant hypersensitivity reaction to SYNAGIS.

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

  • with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
  • with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
  • with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

 

These are not all the possible risks associated with SYNAGIS. Please see full Prescribing Information for SYNAGIS, including Patient Information. To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or the FDA at 1-800-FDA-1088.

For Colorado prescribers, visit synagishcp.com/wac-pricing.